OX40L blockade protects against inflammationdriven fibrosis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 27, 2016, Pages E3901-E3910

  Elhai, Muriel ^a,b   Avouac, Jérôme ^a,b   Hoffmann Vold, Anna Maria ^c   Ruzehaji, Nadira ^a   Amiar, Olivia ^a   Ruiz, Barbara ^a   Brahiti, Hassina ^a   Ponsoye, Matthieu ^a   Fréchet, Maxime ^a   Burgevin, Anne ^a   Pezet, Sonia ^a   Sadoine, Jérémy ^d,e   Guilbert, Thomas ^a   Nicco, Carole ^a   Akiba, Hisaya ^f   Heissmeyer, Vigo ^g,h   Subramaniam, Arun ⁱ   Resnick, Robert ⁱ   Molberg, Øyvind ^c   Kahan, André ^b   Chiocchia, Gilles ^j   Allanore, Yannick ^a,b   more..

^a INSERM   (France)

^b université Paris Cité   (France)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d France   (France)

^e Le Pôle de Recherche et d'Enseignement Supérieur Sorbonne Paris Cité   (France)

^f JUNTENDO UNIVERSITY   (Japan)

^g INSTITUTE OF EPIDEMIOLOGY   (Germany)

^h UNIVERSITY OF MUNICH   (Germany)

ⁱ SANOFI   (France)

^j LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

more..

Author keywords

Costimulation; Fibrosis; OX40L; Systemic sclerosis; Translational approach

Indexed keywords

OX40 LIGAND; BIOLOGICAL MARKER; BLEOMYCIN; FOSL2 PROTEIN, MOUSE; MONOCLONAL ANTIBODY; TNFSF4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FRA 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DERMATITIS; FEMALE; FIBROBLAST; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; LUNG FIBROSIS; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; SKIN FIBROSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CASE CONTROL STUDY; CELL CULTURE; FIBROSIS; GENETICS; HYPERTENSION, PULMONARY; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PRECLINICAL STUDY; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC; SKIN; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOMARKERS; BLEOMYCIN; CASE-CONTROL STUDIES; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; FIBROSIS; FOS-RELATED ANTIGEN-2; HUMANS; HYPERTENSION, PULMONARY; MICE, INBRED C57BL; MICE, TRANSGENIC; MIDDLE AGED; MOLECULAR TARGETED THERAPY; OX40 LIGAND; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC; SKIN; TRANSCRIPTION FACTOR AP-1;

EID: 84977265752     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1523512113     Document Type: Article

References (44)

1. Friedman SL, Sheppard D, Duffield JS, Violette S (2013) Therapy for fibrotic diseases: Nearing the starting line. Sci Transl Med 5(167):167sr1.
2. Varga J, Pasche B (2009) Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 5(4):200-206.
3. Sugamura K, Ishii N, Weinberg AD (2004) Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 4(6):420-431.
4. Ishii N, Takahashi T, Soroosh P, Sugamura K (2010) OX40-OX40 ligand interaction in T-cellmediated immunity and immunopathology. Adv Immunol 105:63-98.
5. Webb GJ, Hirschfield GM, Lane PJL (2016) OX40, OX40L and autoimmunity: A comprehensive review. Clin Rev Allergy Immunol 50(3):312-332.
6. Gourh P, et al. (2010) Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis. Ann Rheum Dis 69(3):550-555.
7. Bossini-Castillo L, et al. (2011) A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. Ann Rheum Dis 70(4):638-641.
8. Coustet B, et al. (2012) Independent replication and meta analysis of association studies establish TNFSF4 as a susceptibility gene preferentially associated with the subset of anticentromere-positive patients with systemic sclerosis. J Rheumatol 39(5):997-1003.
9. Komura K, et al. (2008) Increased serum soluble OX40 in patients with systemic sclerosis. J Rheumatol 35(12):2359-2362.
10. Gwyer Findlay E, et al. (2014) OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis. Proc Natl Acad Sci USA 111(6):2289-2294.
11. Avouac J, et al. (2012) Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis Rheum 64(5):1642-1652.
12. Beyer C, Schett G, Distler O, Distler JHW (2010) Animal models of systemic sclerosis: Prospects and limitations. Arthritis Rheum 62(10):2831-2844.
13. Green MC, Sweet HO, Bunker LE (1976) Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol 82(3):493-512.
14. Tyndall AJ, et al. (2010) Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69(10):1809-1815.
15. Maurer B, et al. (2012) Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Ann Rheum Dis 71(8):1382-1387.
16. Maurer B, et al. (2009) Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. Circulation 120(23):2367-2376.
17. du Bois RM (2007) Mechanisms of scleroderma-induced lung disease. Proc Am Thorac Soc 4(5):434-438.
18. Frech TM, et al. (2013) Treatment of early diffuse systemic sclerosis skin disease. Clin Exp Rheumatol 31(2, Suppl 76):166-171.
19. Higgins LM, et al. (1999) Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: Amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J Immunol 162(1):486-493.
20. Ndhlovu LC, Ishii N, Murata K, Sato T, Sugamura K (2001) Critical involvement of OX40 ligand signals in the T cell priming events during experimental autoimmune encephalomyelitis. J Immunol 167(5):2991-2999.
21. Carboni S, et al. (2003) CD134 plays a crucial role in the pathogenesis of EAE and is upregulated in the CNS of patients with multiple sclerosis. J Neuroimmunol 145(1-2):1-11.
22. Croft M, So T, Duan W, Soroosh P (2009) The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev 229(1):173-191.
23. Ohshima Y, et al. (1997) Expression and function of OX40 ligand on human dendritic cells. J Immunol 159(8):3838-3848.
24. Song J, So T, Croft M (2008) Activation of NF-kappaB1 by OX40 contributes to antigen-driven T cell expansion and survival. J Immunol 180(11):7240-7248.
25. Matsumura Y, Hori T, Kawamata S, Imura A, Uchiyama T (1999) Intracellular signaling of gp34, the OX40 ligand: Induction of c-jun and c-fos mRNA expression through gp34 upon binding of its receptor, OX40. J Immunol 163(6):3007-3011.
26. Murata K, et al. (2002) Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases. J Immunol 169(8):4628-4636.
27. Bagnato G, Harari S (2015) Cellular interactions in the pathogenesis of interstitial lung diseases. Eur Respir Rev 24(135):102-114.
28. Rabieyousefi M, et al. (2011) Indispensable roles of OX40L-derived signal and epistatic genetic effect in immune-mediated pathogenesis of spontaneous pulmonary hypertension. BMC Immunol 12:67.
29. Gauvreau GM, et al. (2014) OX40L blockade and allergen-induced airway responses in subjects with mild asthma. Clin Exp Allergy 44(1):29-37.
30. Humphreys IR, et al. (2003) A critical role for OX40 in T cell-mediated immunopathology during lung viral infection. J Exp Med 198(8):1237-1242.
31. Hoffmann-Vold A-M, et al. (2015) Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis. Arthritis Rheumatol 67(8):2205-2212.
32. Yamamoto T (2010) Animal model of systemic sclerosis. J Dermatol 37(1):26-41.
33. Avouac J, et al. (2013) Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis. Ann Rheum Dis 72(6):1089-1098.
34. Kavian N, et al. (2012) Sunitinib inhibits the phosphorylation of platelet-derived growth factor receptor β in the skin of mice with scleroderma-like features and prevents the development of the disease. Arthritis Rheum 64(6):1990-2000.
35. Avouac J, et al. (2011) Inactivation of the transcription factor STAT-4 prevents inflammationdriven fibrosis in animal models of systemic sclerosis. Arthritis Rheum 63(3):800-809.
36. Kamel H, et al. (1978) Comparison of gold levels and distribution in guinea pig serum. Arthritis Rheum 21(4):441-446.
37. Ashcroft T, Simpson JM, Timbrell V (1988) Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 41(4):467-470.
38. Gailhouste L, et al. (2010) Fibrillar collagen scoring by second harmonic microscopy: A new tool in the assessment of liver fibrosis. J Hepatol 52(3):398-406.
39. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23(5):581-590.
40. LeRoy EC, et al. (1988) Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 15(2):202-205.
41. Humbert M, McLaughlin VV (2009) The 4th world symposium on pulmonary hypertension. J Am Coll Cardiol 54(1 Suppl):S1-117.
42. Clements PJ, et al. (1993) Skin thickness score in systemic sclerosis: An assessment of interobserver variability in 3 independent studies. J Rheumatol 20(11):1892-1896.
43. Hoffmann-Vold A-M, Gunnarsson R, Garen T, Midtvedt Ø, Molberg Ø (2015) Performance of the 2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis (SSc) in large, well-defined cohorts of SSc and mixed connective tissue disease. J Rheumatol 42(1):60-63.
44. Goh NSL, et al. (2008) Interstitial lung disease in systemic sclerosis: A simple staging system. Am J Respir Crit Care Med 177(11):1248-1254.